4-122742008-T-C

Variant summary

Our verdict is Benign. The variant received -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2

The NM_152618.3(BBS12):​c.116T>C​(p.Ile39Thr) variant causes a missense change. The variant allele was found at a frequency of 0.00729 in 1,613,476 control chromosomes in the GnomAD database, including 55 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.0057 ( 2 hom., cov: 33)
Exomes 𝑓: 0.0075 ( 53 hom. )

Consequence

BBS12
NM_152618.3 missense

Scores

3
11
5

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications U:2B:12

Conservation

PhyloP100: 7.05

Publications

15 publications found
Variant links:
Genes affected
BBS12 (HGNC:26648): (Bardet-Biedl syndrome 12) The protein encoded by this gene is part of a complex that is involved in membrane trafficking. The encoded protein is a molecular chaperone that aids in protein folding upon ATP hydrolysis. This protein also plays a role in adipocyte differentiation. Defects in this gene are a cause of Bardet-Biedl syndrome type 12. Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, May 2010]
BBS12 Gene-Disease associations (from GenCC):
  • Bardet-Biedl syndrome 12
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), Genomics England PanelApp, G2P, Ambry Genetics, Myriad Women’s Health
  • ciliopathy
    Inheritance: AR Classification: DEFINITIVE Submitted by: ClinGen
  • Bardet-Biedl syndrome
    Inheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -13 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.009558558).
BP6
Variant 4-122742008-T-C is Benign according to our data. Variant chr4-122742008-T-C is described in ClinVar as Conflicting_classifications_of_pathogenicity. ClinVar VariationId is 96504.
BS1
Variant frequency is greater than expected in population amr. GnomAd4 allele frequency = 0.00568 (865/152324) while in subpopulation AMR AF = 0.0114 (175/15294). AF 95% confidence interval is 0.0101. There are 2 homozygotes in GnomAd4. There are 387 alleles in the male GnomAd4 subpopulation. Median coverage is 33. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 2 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
BBS12NM_152618.3 linkc.116T>C p.Ile39Thr missense_variant Exon 2 of 2 ENST00000314218.8 NP_689831.2 Q6ZW61
BBS12NM_001178007.2 linkc.116T>C p.Ile39Thr missense_variant Exon 3 of 3 NP_001171478.1 Q6ZW61
BBS12XM_011531680.3 linkc.116T>C p.Ile39Thr missense_variant Exon 2 of 2 XP_011529982.1 Q6ZW61

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
BBS12ENST00000314218.8 linkc.116T>C p.Ile39Thr missense_variant Exon 2 of 2 1 NM_152618.3 ENSP00000319062.3 Q6ZW61
BBS12ENST00000542236.5 linkc.116T>C p.Ile39Thr missense_variant Exon 3 of 3 2 ENSP00000438273.1 Q6ZW61
BBS12ENST00000433287.1 linkc.116T>C p.Ile39Thr missense_variant Exon 3 of 3 2 ENSP00000398912.1 C9J8H7

Frequencies

GnomAD3 genomes
AF:
0.00568
AC:
865
AN:
152206
Hom.:
2
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00118
Gnomad AMI
AF:
0.00220
Gnomad AMR
AF:
0.0115
Gnomad ASJ
AF:
0.0153
Gnomad EAS
AF:
0.000192
Gnomad SAS
AF:
0.00394
Gnomad FIN
AF:
0.000941
Gnomad MID
AF:
0.00949
Gnomad NFE
AF:
0.00794
Gnomad OTH
AF:
0.00621
GnomAD2 exomes
AF:
0.00631
AC:
1584
AN:
251186
AF XY:
0.00689
show subpopulations
Gnomad AFR exome
AF:
0.00105
Gnomad AMR exome
AF:
0.00550
Gnomad ASJ exome
AF:
0.0122
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00250
Gnomad NFE exome
AF:
0.00862
Gnomad OTH exome
AF:
0.00948
GnomAD4 exome
AF:
0.00746
AC:
10893
AN:
1461152
Hom.:
53
Cov.:
31
AF XY:
0.00758
AC XY:
5511
AN XY:
726770
show subpopulations
African (AFR)
AF:
0.00105
AC:
35
AN:
33432
American (AMR)
AF:
0.00526
AC:
235
AN:
44672
Ashkenazi Jewish (ASJ)
AF:
0.0147
AC:
384
AN:
26126
East Asian (EAS)
AF:
0.00
AC:
0
AN:
39678
South Asian (SAS)
AF:
0.00471
AC:
406
AN:
86200
European-Finnish (FIN)
AF:
0.00227
AC:
121
AN:
53408
Middle Eastern (MID)
AF:
0.0118
AC:
68
AN:
5764
European-Non Finnish (NFE)
AF:
0.00829
AC:
9218
AN:
1111504
Other (OTH)
AF:
0.00706
AC:
426
AN:
60368
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.504
Heterozygous variant carriers
0
699
1398
2096
2795
3494
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
338
676
1014
1352
1690
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.00568
AC:
865
AN:
152324
Hom.:
2
Cov.:
33
AF XY:
0.00520
AC XY:
387
AN XY:
74490
show subpopulations
African (AFR)
AF:
0.00118
AC:
49
AN:
41574
American (AMR)
AF:
0.0114
AC:
175
AN:
15294
Ashkenazi Jewish (ASJ)
AF:
0.0153
AC:
53
AN:
3472
East Asian (EAS)
AF:
0.000193
AC:
1
AN:
5188
South Asian (SAS)
AF:
0.00394
AC:
19
AN:
4824
European-Finnish (FIN)
AF:
0.000941
AC:
10
AN:
10624
Middle Eastern (MID)
AF:
0.0102
AC:
3
AN:
294
European-Non Finnish (NFE)
AF:
0.00794
AC:
540
AN:
68030
Other (OTH)
AF:
0.00615
AC:
13
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
45
90
135
180
225
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00790
Hom.:
20
Bravo
AF:
0.00587
TwinsUK
AF:
0.00593
AC:
22
ALSPAC
AF:
0.0101
AC:
39
ESP6500AA
AF:
0.00113
AC:
5
ESP6500EA
AF:
0.00767
AC:
66
ExAC
AF:
0.00608
AC:
738
Asia WGS
AF:
0.000577
AC:
2
AN:
3478
EpiCase
AF:
0.0114
EpiControl
AF:
0.0111

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:12
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

not specified Benign:5
-
Clinical Genetics, Academic Medical Center
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Sep 04, 2018
Genetic Services Laboratory, University of Chicago
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 22, 2022
Women's Health and Genetics/Laboratory Corporation of America, LabCorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

Variant summary: BBS12 c.116T>C (p.Ile39Thr) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0063 in 251186 control chromosomes in the gnomAD database, including 6 homozygotes. The observed variant frequency is approximately 8 fold of the estimated maximal expected allele frequency for a pathogenic variant in BBS12 causing Bardet-Biedl Syndrome phenotype (0.00076), strongly suggesting that the variant is benign. c.116T>C has been reported in the literature in individuals affected with Bardet-Biedl Syndrome. These report(s) do not provide unequivocal conclusions about association of the variant with Bardet-Biedl Syndrome. At-least one co-occurrence with other pathogenic variant(s) have been reported (BBS12 c.814C>T, p.Arg272*), providing supporting evidence for a benign role (example, Manara_2019). One publication reports experimental evidence evaluating an impact on protein function, however, does not allow convincing conclusions about the variant effect (Zaghoul_2010). Seven clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. Multiple laboratories reported the variant with conflicting assessments. Based on the evidence outlined above, the variant was classified as likely benign. -

-
PreventionGenetics, part of Exact Sciences
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 20, 2013
Eurofins Ntd Llc (ga)
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Bardet-Biedl syndrome 12 Uncertain:2Benign:2
Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as likely benign is not then subjected to further curation. The score for this variant resulted in a classification of likely benign for this disease. -

May 18, 2021
Genome-Nilou Lab
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Nov 13, 2019
Natera, Inc.
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Dec 18, 2017
Genomic Research Center, Shahid Beheshti University of Medical Sciences
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Bardet-Biedl syndrome 1 Benign:2
Dec 22, 2014
Genome Diagnostics Laboratory, University Medical Center Utrecht
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 19, 2017
Genome Diagnostics Laboratory, Amsterdam University Medical Center
Significance:Likely benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

not provided Benign:2
May 09, 2017
Center for Pediatric Genomic Medicine, Children's Mercy Hospital and Clinics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Mar 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

BBS12: BS2 -

Bardet-Biedl syndrome Benign:1
Feb 01, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
0.41
BayesDel_addAF
Uncertain
0.054
T
BayesDel_noAF
Pathogenic
0.31
CADD
Uncertain
23
DANN
Uncertain
1.0
DEOGEN2
Uncertain
0.68
D;D;.
Eigen
Uncertain
0.66
Eigen_PC
Uncertain
0.64
FATHMM_MKL
Pathogenic
0.98
D
LIST_S2
Benign
0.74
T;.;T
M_CAP
Benign
0.050
D
MetaRNN
Benign
0.0096
T;T;T
MetaSVM
Uncertain
0.28
D
MutationAssessor
Uncertain
2.7
M;M;.
PhyloP100
7.0
PrimateAI
Benign
0.45
T
PROVEAN
Uncertain
-3.4
D;D;D
REVEL
Pathogenic
0.66
Sift
Uncertain
0.0020
D;D;D
Sift4G
Uncertain
0.0040
D;D;D
Polyphen
0.99
D;D;.
Vest4
0.78
MVP
0.92
MPC
0.43
ClinPred
0.0081
T
GERP RS
5.0
Varity_R
0.83
gMVP
0.59
Mutation Taster
=93/7
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs138036823; hg19: chr4-123663163; API